Dufalak Frut (lactulose) oral solution 667 mg/ml. 200 ml. vial


Manufacturer: Netherlands

constipation; hepatic encephalopathy; conditions that require relief of defecation ( hemorrhoids, after operations on the large intestine or anorectal area).



Dufalak Frut Composition
active substance: lactulose, liquid;

1 ml of liquid contains: 667 mg of lactulose, liquid;

Dufalak Frut excipients: plum flavoring 1.

1 natural plum flavor ZINSD (with another natural flavor).

Dufalak Frut Dosage form
Oral solution.

Basic physical and chemical properties: transparent, viscous liquid, from colorless to brownish-yellow.

Pharmacotherapeutic group
Osmotic laxatives. ATX code A06A D11.

In the large intestine, lactulose is broken down by intestinal bacteria to low molecular weight organic acids. These acids lower the pH in the lumen of the colon and, due to the osmotic effect, increase the volume of intestinal contents. These effects stimulate the peristalsis of the large intestine and normalize the consistency of feces. Constipation is corrected and the physiological rhythm of the large intestine is restored.

In hepatic encephalopathy, the effect of the drug is due to inhibition of the growth of proteolytic bacteria due to an increase in the number of acidophilic bacteria (for example, lactobacilli), the transformation of ammonia into an ionized form due to acidification of the contents of the large intestine, a laxative effect due to low pH in the large intestine, as well as the osmotic effect, a change in bacterial metabolism nitrogen by stimulating the utilization of ammonia by bacteria for the synthesis of bacterial proteins. In the context of the above, it should be noted, however, that the neuropsychiatric manifestations of hepatic encephalopathy cannot be explained by hyperammonemia alone. However, ammonia can serve as a model compound for other nitro compounds.

Lactulose as a prebiotic enhances the growth of beneficial bacteria such as bifidobacteria and lactobacilli, while the growth of potentially pathogenic bacteria such as clostridia and E. coli can be suppressed. This leads to a more favorable balance of intestinal flora and elimination of constipation, favorably affects the quality of life and health.

Lactulose is poorly absorbed after oral administration and reaches the large intestine unchanged. There it is metabolized by the bacterial flora of the large intestine. When used in doses of 25-50 g or 40-75 ml, lactulose is completely metabolized. When using high doses, some may be excreted unchanged.

Constipation: regulation of the physiological rhythm of the large intestine.
Conditions requiring relief of bowel movements (eg, hemorrhoids, conditions after colon / anorectal surgery).
Hepatic encephalopathy: treatment and prevention of hepatic coma or precoma.

Hypersensitivity to the active substance or to any of the components of the drug.
Gastrointestinal obstruction, perforation of the digestive tract, or risk of perforation of the digestive tract (eg, acute inflammatory bowel disease such as ulcerative colitis, Crohn’s disease).
Interaction with other medicinal products and other forms of interaction
Interaction studies have not been conducted.

Lactulose can increase potassium loss induced by other drugs (eg, thiazides, corticosteroids, and amphotericin B). Concomitant use with cardiac glycosides can increase the effect of glycosides due to potassium deficiency.